Contraline is a medical device company devoted to providing men and couples with long-lasting, safe and effective male contraception. Currently in the process of developing ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men; ASV’s investment will support Contraline in the initiation of its first-in-human trial. This trial on ADAM is believed to be the first clinical trial on a non-hormonal male contraceptive device in over 20 years.
Kevin Eisenfrats, Co-Founder and CEO of Contraline, recently said of their ambitions, “We have completed preclinical R&D and manufacturing of the ADAM System to be used in humans, and we now have the financing, ethics approval, and team in place to transition ADAM into clinical trials. It’s been over 60 years since the hormonal female pill was launched, with few innovations for either men or women.”
Carli Sapir, Founding Partner or Amboy Street Ventures, said, “With existing contraceptive options available today, the large burden of pregnancy prevention falls on women. As a contraceptive option for men, Contraline aligns with our commitment to investing in the democratization of sexual health for all genders.”
Contraline is the latest brand to join ASV’s growing portfolio of brands at the forefront of social change in the industry including Dipsea, an audio erotica platform where sexual wellness meets storytelling, Gennev, the digital health platform for women in menopause and Dame Products, a leading female-focused sexual wellness brand
.jpeg)
